Heading into 2024, BB Biotech AG finds itself in a swiftly changing environment, shaped by pivotal shifts in capital markets, technological breakthroughs and healthcare regulations. Our strategy aims to respond adeptly to these dynamics, refining our investment approaches and seizing new opportunities that arise. We will closely track the market reception of innovative products like Casgevy, the pioneering gene editing therapy, and anticipate key proof of concept results from cutting-edge technologies, including in vivo gene editing. Moreover, the surge in M&A activities observed in 2023 is poised to continue, playing a crucial role in driving biotech industry growth and delivering value to investors.

Sustainability is an important factor in BB Biotech’s business strategy. It is a key component in ensuring our long-term success while creating added value for all our shareholders and other stakeholders. We seek to achieve growth while also taking into account the needs of the environment and society. As an investment company, we are in a position to promote sustainable development for the benefit of all our stakeholders.